Katakura Industries Co., Ltd. · TSE:3001
Katakura Industries — FY2022 Earnings Presentation
21 slides from Katakura Industries's earnings presentation, Feb 28, 2023
Slide 1: Financial Results of 2022
Financial Results of 2022 (Code 3001, TSE Standard Market) February 28, 2023 Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
Slide 2: Contents
Contents Financial Results of 2022 1. Financial Highlights of 2022 Consolidated Income Statement Consolidated Income Statement / Business Segment Consolidated Balance Sheet Consolidated Statement of Cash Flows Capital Expenditures, Depreciation and R&D Expenditures 2. 2023 Forecast Consolidated Inco
Slide 3: 1. Financial Highlights of 2022
1. Financial Highlights of 2022 3
Slide 4: Consolidated Income Statement
Consolidated Income Statement Financial Results of 2022 （Million yen） 2022 Actual 2021 Actual YoY change Ａ Ｂ A-B Net sales 34,274 37,627 (3,353) Operating income 1,369 2,797 (1,428) Operating income ratio 4.0% 7.4% (3.4)pt Ordinary income 2,582 3,855 (1,273) Extraordinary income 1,199 3,914 (2,715)
Slide 5: Consolidated Income Statement / Business Segment
Consolidated Income Statement / Business Segment Financial Results of 2022 （Million yen） 2022 Actual 2021 Actual YoY change Ａ Ｂ A-B Net sales Operating income Net sales Operating income Net sales Operating income Real Estate 10,415 3,946 10,125 3,590 ① 290 356 Pharmaceuticals 10,128 (1,940) 12,132 1
Slide 6: Consolidated Balance Sheet
Consolidated Balance Sheet Financial Results of 2022 （Million yen） 2022.12 2021.12 YoY change A B A-B Current assets 56,379 57,059 (680) Non-current assets 81,734 82,914 (1,180) Property, plant and equipment 43,171 44,789 (1,618) • Down due to depreciation Intangible assets 337 361 (24) Investments
Slide 7: Consolidated Statement of Cash Flows
Consolidated Statement of Cash Flows Financial Results of 2022 （Million yen） 2022 Actual 2021 Actual Cash and cash equivalents at beginning of year 10,813 8,017 Operating cash flows (712) 4,604 Investing cash flows 3,623 2,250 Financing cash flows (3,262) (4,059) Net increase (decrease) in cash and
Slide 8: Capital Expenditures, Depreciation and R&D Expenditures
Capital Expenditures, Depreciation and R&D Expenditures Financial Results of 2022 （Million yen） 2022 Actual 2021 Actual YoY change A B A-B Real Estate 103 311 (208) Pharmaceuticals 564 1,040 ① (476) ① Upgraded packaging machines and introduced video inspection devices in pharmaceuticals in FY2021 Ot
Slide 9: 2. 2023 Forecast
4 KATAKURA 2. 2023 Forecast
Slide 10: Consolidated Income Statement / Forecast
Consolidated Income Statement / Forecast Financial Results of 2022 （Million yen） 2023 Forecast 2022 Actual YoY change A B A-B Net sales 38,500 34,274 4,226 Operating income 2,850 1,369 1,481 Operating income ratio 7.4% 4.0% 3.4pt Ordinary income 4,000 2,582 1,418 Profit attributable to owners of par
Slide 11: Consolidated Income Statement / Business Segment Forecast
Consolidated Income Statement / Business Segment Forecast Financial Results of 2022 （Million yen） 2023 Forecast 2022 Actual YoY change A B A-B Net sales Operating income Net sales Operating income Net sales Operating income Real Estate 10,400 3,650 10,415 3,946 ① (15) (296) Pharmaceuticals 13,400 10
Slide 12: Capital Expenditures, Depreciation and R&D Expenditures Forecast
Capital Expenditures, Depreciation and R&D Expenditures Forecast Financial Results of 2022 （Million yen） 2023 Forecast 2022 Actual YoY change A B A-B Real Estate 322 103 219 Pharmaceuticals 634 564 70 Other segments 505 283 222 Capital expenditures 1,461 950 511 Real Estate 1,359 1,490 (131) Pharmac
Slide 13: 3. Priority Issues to be Addressed
3. Priority Issues to be Addressed 13
Slide 14: Situation after Structural Reforms and Priority Issues to be Addressed
Situation after Structural Reforms and Priority Issues to be Addressed Financial Results of 2022 2017 Announced the Medium-term Management Plan “Katakura 2021” Embarked on structural reforms to shift our focus to growing businesses 2018– Withdrew from operations of two affiliated subsidiaries; aboli
Slide 15: Pharmaceuticals: Response Policy Based on External Environment
Pharmaceuticals: Response Policy Based on External Environment Financial Results of 2022 Annual NHI drug price revisions starting in FY2021 Quality issues arising in the generic drug market Environment External ➢ Concerns over quality and stable supply of generic drugs; Rapid changes eroded conf
Slide 16: Textiles: Structural Reforms of Practical Clothing and Enhancement of Functional Fibers
Textiles: Structural Reforms of Practical Clothing and Enhancement of Functional Fibers Financial Results of 2022 Practical clothing business The Company will transfer its practical clothing business to a consolidated subsidiary Ogran Japan Co., Ltd. in May 2023 (to further drive the structural re
Slide 17: Machinery: Sales Period Carried Forward and Structural Reforms (Future Measures)
Machinery: Sales Period Carried Forward and Structural Reforms (Future Measures) Financial Results of 2022 Sales period carried forward due to delays in chassis reception 2022, Jan. Apr. Jul. Oct. 2023, Jan. Apr. Jul. Oct. 2024, Jan. FY2022 (consolidated) FY2023 (consolidated) Fiscal period Nihon
Slide 18: Real Estate: Current Business Overview and Future Initiatives
Real Estate: Current Business Overview and Future Initiatives Financial Results of 2022 Saw a steady recovery in sales at the COCOON CITY, seeking to further improve its freshness and attractiveness Sales at the shopping center steadily recovered to the pre-pandemic level thanks to initiatives tak
Slide 19: Development of Foundational Structures
Development of Foundational Structures Financial Results of 2022 Improve compliance Strengthen risk management ▶ Implement the PDCA cycle by introducing ▶ Strengthen the risk management structure by compliance programs expanding the authority of the “Risk Management Committee” to cover the entire ▶
Slide 20: 4. Dividends and Dividend Policy
4. Dividends and Dividend Policy 20
Slide 21: Shareholder Returns (Dividends)
Shareholder Returns (Dividends) Financial Results of 2022 Dividend Policy • The Company regards returning profits to shareholders as one of our important management policies. • The basic policy for allocating earnings is to pay a consistent and stable dividend to shareholders while taking into accou